DexCom (NASDAQ:DXCM) EVP Sadie Stern Sells 2,565 Shares of Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Sadie Stern sold 2,565 shares of the company’s stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $88.37, for a total transaction of $226,669.05. Following the completion of the sale, the executive vice president directly owned 126,043 shares in the company, valued at $11,138,419.91. This represents a 1.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Stock Up 1.7%

NASDAQ DXCM traded up $1.53 during trading hours on Friday, reaching $90.82. 2,544,135 shares of the company’s stock traded hands, compared to its average volume of 5,235,547. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $92.59. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43. The firm has a 50-day simple moving average of $78.84 and a 200 day simple moving average of $71.47. The firm has a market cap of $34.27 billion, a PE ratio of 35.90, a PEG ratio of 1.50 and a beta of 1.41.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The business had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.29 billion. During the same quarter in the prior year, the company earned $0.48 earnings per share. The business’s revenue was up 13.1% compared to the same quarter last year. Sell-side analysts anticipate that DexCom, Inc. will post 2.64 EPS for the current fiscal year.

Institutional Trading of DexCom

Institutional investors have recently made changes to their positions in the stock. Reflection Asset Management bought a new position in DexCom during the fourth quarter valued at approximately $25,000. Ascentis Independent Advisors purchased a new stake in DexCom during the 1st quarter valued at $25,000. MCF Advisors LLC purchased a new stake in DexCom during the 4th quarter valued at $32,000. Wellington Grp LLC lifted its holdings in shares of DexCom by 778.7% during the 1st quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock valued at $34,000 after buying an additional 475 shares during the period. Finally, DV Equities LLC purchased a new position in shares of DexCom in the 4th quarter worth $36,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have issued reports on DXCM. BTIG Research reiterated a “buy” rating and set a $90.00 price objective (up from $80.00) on shares of DexCom in a research note on Friday, July 31st. Canaccord Genuity Group set a $90.00 price target on DexCom and gave the stock a “buy” rating in a research report on Monday, August 3rd. Citigroup reissued a “buy” rating and set a $88.00 price objective (up from $84.00) on shares of DexCom in a research report on Friday, July 31st. Piper Sandler reaffirmed an “overweight” rating and issued a $95.00 target price (up from $88.00) on shares of DexCom in a report on Friday, July 31st. Finally, Wall Street Zen downgraded shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 10th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $88.71.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.